Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Shares Shorted: Short Interest Down 59.6% in October

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) was the recipient of a large decline in short interest in October. As of October 15th, there was short interest totaling 33,053 shares, a decline of 59.6% from the September 30th total of 81,750 shares. Based on an average daily trading volume, of 679,428 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

CHGCY has been the subject of a number of recent research reports. Nomura upgraded Chugai Pharmaceutical to a “hold” rating in a research note on Tuesday, September 1st. UBS Group lowered shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Price Performance

Shares of CHGCY opened at $20.98 on Thursday. The firm has a market cap of $69.05 billion, a P/E ratio of 22.80 and a beta of 0.60. Chugai Pharmaceutical has a 1 year low of $18.33 and a 1 year high of $34.84. The company has a 50 day simple moving average of $20.76 and a two-hundred day simple moving average of $24.58.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its earnings results on Tuesday, October 27th. The company reported $0.27 EPS for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. The firm had revenue of $2.54 billion for the quarter, compared to the consensus estimate of $2.29 billion. On average, sell-side analysts anticipate that Chugai Pharmaceutical will post 1.00 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.

The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.

Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.